Regeneron Pharmaceuticals' stock surged 12% after reporting a 36% revenue increase to $5.1 billion in Q3 2026, beating analyst expectations. The boost was largely due to its partnership with Sanofi, with Dupixent sales rising 35%, and record sales of Eylea HD and Libtayo. Regeneron also raised its full-year margin guidance and expects a $1 billion upfront payment from an expanded Sanofi collaboration. Investors await the FDA's November decision on cemdisiran, which could impact future growth amid risks like biosimilar competition and pricing pressures.
Regeneron Pharmaceuticals shares jumped 11.82% to USD 915.56 on Pluang as of Oct 30, 2026 22:21 WIB, closely matching the reported 12% surge. Sanofi's stock also rose by 3.36% to USD 44.58, reflecting positive investor sentiment around its collaboration with Regeneron. Meanwhile, Moderna showed a modest increase of 0.31% to USD 223.46 during the same period, indicating more subdued market reaction.
Regeneron reported a 36% revenue increase to $5.1 billion in Q3 2026, with record sales for Dupixent, EYLEA HD, and Libtayo. GAAP EPS rose 35% to $18.45, and non-GAAP EPS jumped 70% to $20.07. The company expanded its collaboration with Sanofi, secur...
Regeneron will report its Q3 earnings on October 30, marking the first quarter it fully books its share of Dupixent profits from Sanofi after repaying a $3.1 billion development balance. This change is expected to significantly boost collaboration re...
Regeneron Pharmaceuticals has extended its agreement with the U.S. government's BARDA to supply additional doses of Inmazeb, an FDA-approved antibody treatment for Ebola caused by Orthoebolavirus zairense. The expanded deal, valued at approximately $...
